Q-omics provides the consensus-scored NAGS profile across patient tissues and cancer cell-line models. NAGS expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NAGS is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, NAGS RNA expression shows 18,575 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where NAGS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAGS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAGS survival associations across molecular data types. NAGS RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAGS RNA expression–survival associations across cancer types. High NAGS expression shows unfavorable associations in ACC, UVM, KIRC, PAAD and LUSC, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NAGS RNA expression.
This table summarizes NAGS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NAGS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAGS shows lower tumor expression in KIRP, KIRC, LUSC and THCA and higher tumor expression in HNSC and BLCA. The HNSC box plot shows higher NAGS RNA expression in tumor versus normal tissue (log2 FC = +1.726, t-test p < 0.001).
This table shows molecular features associated with NAGS in patient tissues and cancer cell lines. In patient samples, NAGS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NAGS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
